Pricing reflects SkinnyRxs published rates and may change
Liver Int 26(8): 1015-17 Wettergren A et al (1998): Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow
Pre-treatment HbA1C, subject age, ALT, AST, BMI, metformin use, and having hypertension each positively contribute to predicted GLP-1 M responsiveness
The 0.25 mg dose is an initial titration dose designed to improve tolerability, not for glycaemic control, and elimination time is identical across all doses
The conversion charts available through SeekPeptides provide the best available guidance based on clinical data and documented patient experiences, but individual adjustment is always necessary
Many people microdosing GLP-1 medications are taking a compounded GLP-1, which means the drug was made in a compounded pharmacy and not approved by the FDA for safety, quality or efficiency